MCENANY PATRICK J

Director McEnany sells 200,000 CPRX shares for $5.2M in two tranches; stock near 52-week high at $26.31.

Patrick J. McEnany, a director of Catalyst Pharmaceuticals, executed 2 separate sales totaling 200,000 shares for $5,217,338.42 between June 6 and June 9, 2025, at a blended average price of $26.09 per share. The current price of $26.31 is at the 52-week high, and the stock has gained 12.6% over the last 30 days and 24.1% over 90 days, indicating a period of strong upward momentum. McEnany retains 4,281,702 shares post-transaction, reducing his holdings by 4.5%. His prior sales at this ticker (5 trades in late November 2024) showed mixed timing outcomes, with 2 of 5 being well-timed at the 90-day mark; however, his cross-ticker track record shows a 57.14% well-timed rate across 7 prior sells with an average 90-day return of +1.8%, suggesting his sells have historically underperformed (selling before upside rather than before declines). The fundamentals show strong performance with $141.4M in latest-quarter revenue, $56.7M net income, and 23.5% annual revenue growth at a P/E of 16.24.

CPRX Director McEnany sells 170,845 shares (170.8K) for $3,627,258.86 across two days; holds 4,478,169 shares post-sale as stock near 52-week high.

Director Patrick J. McEnany executed 2 separate sales totaling 170,845 shares for $3,627,258.86 on 2024-11-19 and 2024-11-20 at a blended average price of $21.23, reducing his holdings by 3.7% from 4,649,014 shares to 4,478,169 shares. The sale occurred when CPRX was trading near its 52-week high of $23.93 (current price $21.12 is -11.7% from that peak), and McEnany retains substantial ownership at 4.48M shares. His prior trading pattern at CPRX shows 5 recent consecutive sells (2024-11-11 through 2024-11-14), indicating a sustained reduction phase rather than an isolated transaction. Against the company's strong recent fundamentals—revenue of $128,695,000, net income of $43,884,000, and annual growth of +85.9%—the concentrated selling activity warrants attention to whether the director's risk/reward assessment at current valuations differs from the broader company outlook.

Director Patrick McEnany sold 137,155 shares (137.2K) at $22.98–$21.75 for $3.1M total; stock now $20.60.

Director McEnany executed two separate sales on consecutive days (November 13–14, 2024), totaling 137,155 shares for $3,096,800.56 at a blended average price of $22.58. This reduced his holdings from 4,615,324 to 4,478,169 shares—a -3.0% reduction in his position. The current stock price of $20.60 is 13.9% below the 52-week high of $23.93, and the sales occurred near the recent price range highs, with the stock now trading below both transaction prices. McEnany's prior three trades at CPRX (all within the past 3 days) have not yet accumulated sufficient history to assess timing pattern. The company reports strong fundamentals: annual revenue growth of +85.9%, net income of $43,884,000.00, and a P/E of 17.17, suggesting the stock is not driven by distressed conditions. The pattern of consecutive daily sales warrants monitoring for context regarding liquidity needs, portfolio rebalancing, or other strategic rationale.

Director Patrick McEnany sells 492,000 shares (492.0K shares) at blended avg $23.39 for $11.5M at CPRX in 3 separate sales.

Patrick McEnany, a director at Catalyst Pharmaceuticals, executed 3 separate sales on November 11–12, 2024, totaling 492,000 shares (492.0K shares) for $11,510,102.00 ($11.5M) at prices ranging from $23.20 to $23.55. This reduces his holdings from 4,970,169 shares (4.97M shares) to 4,478,169 shares (4.48M shares), representing a -9.9% reduction. The sales occurred near the stock's 52-week high of $23.93, with the blended average price of $23.39 capturing near-peak valuation relative to the current price of $22.80. The company's fundamentals remain strong—Revenue $128,695,000.00 ($128.7M) in the latest quarter, Net income $43,884,000.00 ($43.9M), and Annual revenue growth (FY vs prior FY) of +85.9%—indicating no apparent operational distress driving the transaction. With only 1 prior sell in his cross-ticker track record and no measurable 90-day outcomes available for this same-ticker transaction, the pattern does not yet establish a timing consistency either favorable or unfavorable.